Galapagos (GB:0JXZ)
LSE:0JXZ
0JXZ Stock Chart & Stats
€28.40
€0.10(0.38%)
At close: 4:00 PM EST
€28.40
€0.10(0.38%)
Day’s Range― - ―
52-Week Range€19.99 - €32.70
Previous CloseN/A
Volume42.14K
Average Volume (3M)9.16K
Market Cap
€1.67B
Enterprise Value€1.60B
Total Cash (Recent Filing)€3.00B
Total Debt (Recent Filing)€12.10M
Price to Earnings (P/E)5.7
Beta0.69
Next Earnings
May 06, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.87
Shares Outstanding65,897,070
10 Day Avg. Volume4,733
30 Day Avg. Volume9,162
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.75Price Target Upside-19.89% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.15
Revenue Forecast (FY)€105.32M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetThe company’s minimal debt against multibillion equity provides durable financial flexibility. Low leverage reduces refinancing and interest risk, supports funding R&D and trials from reserves, and allows strategic partnering or selective M&A without immediate capital stress over the next months.
Profitability Rebound And Revenue ScaleA material 2024–2025 earnings rebound and sizeable revenue run‑rate indicate the business is moving toward operating-scale performance. Sustained profitability supports reinvestment in the pipeline, strengthens commercial footing, and improves negotiating leverage with partners in the medium term.
Strong Revenue And EPS Growth TrendsVery high reported revenue and EPS growth rates reflect successful commercialization or milestone monetization. Continued top-line and EPS expansion enhances the firm’s ability to self-fund programs, attract partners, and justify longer-term resource allocation over the coming quarters.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative OCF and FCF across 2020–2025 is a structural weakness: ongoing cash burn increases dependence on cash reserves, milestone receipts, or external financing. This raises dilution or spending‑cut risks and constrains ability to sustainably fund clinical programs without partner support.
Volatile Earnings History And Reliance On Non‑recurring ItemsPrior multi-year losses and uneven results signal earnings volatility and potential dependence on one‑off milestones or partner payments. That undermines predictable cash generation and complicates medium-term forecasting, making long-term program funding and valuation of recurring earnings less certain.
Decline In Total Assets Over 2022–2025A shrinking asset base, even with low leverage, can indicate reduced invested capacity or asset disposals. Over the medium term this may limit operational scale, impede ability to expand programs, or signal contraction unless reversed by new investments or asset additions.
Galapagos News
0JXZ FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest share price was €19.99 and its highest was €32.70 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.67B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is May 06, 2026 which is in 36 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Feb 23, 2026. The company reported €11.87 earnings per share for the quarter, beating the consensus estimate of -€0.11 by €11.98.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.82.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €11.87 in its last earnings report, beating expectations of -€0.11. Following the earnings report the stock price went up 5.934%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GB:0JXZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
0JXZ Stock 12 Month Forecast
Average Price Target
€22.75
▼(-19.89% Downside)
Technical Analysis
Options Prices
Currently, No data available
---